Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 28;10(4):600-607.
doi: 10.14218/JCTH.2021.00348. Epub 2022 Jan 4.

A K-nearest Neighbor Model to Predict Early Recurrence of Hepatocellular Carcinoma After Resection

Affiliations

A K-nearest Neighbor Model to Predict Early Recurrence of Hepatocellular Carcinoma After Resection

Chuanli Liu et al. J Clin Transl Hepatol. .

Abstract

Background and aims: Patients with hepatocellular carcinoma (HCC) surgically resected are at risk of recurrence; however, the risk factors of recurrence remain poorly understood. This study intended to establish a novel machine learning model based on clinical data for predicting early recurrence of HCC after resection.

Methods: A total of 220 HCC patients who underwent resection were enrolled. Classification machine learning models were developed to predict HCC recurrence. The standard deviation, recall, and precision of the model were used to assess the model's accuracy and identify efficiency of the model.

Results: Recurrent HCC developed in 89 (40.45%) patients at a median time of 14 months from primary resection. In principal component analysis, tumor size, tumor grade differentiation, portal vein tumor thrombus, alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II (PIVKA-II), aspartate aminotransferase, platelet count, white blood cell count, and HBsAg were positive prognostic factors of HCC recurrence and were included in the preoperative model. After comparing different machine learning methods, including logistic regression, decision tree, naïve Bayes, deep neural networks, and k-nearest neighbor (K-NN), we choose the K-NN model as the optimal prediction model. The accuracy, recall, precision of the K-NN model were 70.6%, 51.9%, 70.1%, respectively. The standard deviation was 0.020.

Conclusions: The K-NN classification algorithm model performed better than the other classification models. Estimation of the recurrence rate of early HCC can help to allocate treatment, eventually achieving safe oncological outcomes.

Keywords: Hepatocellular carcinoma; Machine learning; Prognostic model; Recurrence; Surgical resection.

PubMed Disclaimer

Conflict of interest statement

JL has been an editorial board member of Journal of Clinical and Translational Hepatology since 2021. The other authors have no conflict of interests related to this publication.

Figures

Fig. 1
Fig. 1. Study cohort selection.
Fig. 2
Fig. 2. Algorithm flow.
K-NN, k-nearest neighbor; NB, naïve Bayes; DNN, deep neural networks.
Fig. 3
Fig. 3. Variable importance plot for predicting tumor recurrence showing absolute values of Spearman correlation coefficients between markers and HCC recurrence.
AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; AST, aspartate amino transferase; WBC, white blood cells; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; TBiL, total bilirubin; RBC, red blood cell; PT, prothrombin time; IB, indirect bilirubin; PTA, prothrombin activity.
Fig. 4
Fig. 4. Accuracy, recall rate, true negative rate, precision, and standard deviation of different algorithms.
K-NN, k-nearest neighbor; NB, naïve Bayes; DNN, deep neural networks; ACC, accuracy; TPR, recall rate; TNR, true negative rate; SD, standard deviation.

Similar articles

Cited by

References

    1. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi: 10.1002/hep.29086. - DOI - PubMed
    1. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi: 10.1016/j.jhep.2018.03.019. - DOI - PubMed
    1. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi: 10.1002/hep.29913. - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Zheng Q, Xu J, Gu X, Wu F, Deng J, Cai X, et al. Immune checkpoint targeting TIGIT in hepatocellular carcinoma. Am J Transl Res. 2020;12(7):3212–3224. - PMC - PubMed